Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | coagulation factor VII (serum prothrombin conversion accelerator) | References | |
Homo sapiens | protein C (inactivator of coagulation factors Va and VIIIa) | Starlite/ChEMBL | References |
Homo sapiens | protease, serine, 3 | Starlite/ChEMBL | References |
Homo sapiens | protease, serine, 1 (trypsin 1) | References | |
Homo sapiens | kallikrein 1 | Starlite/ChEMBL | References |
Homo sapiens | Coagulation factor VII/tissue factor | Starlite/ChEMBL | References |
Homo sapiens | kallikrein B, plasma (Fletcher factor) 1 | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor X | Starlite/ChEMBL | References |
Homo sapiens | coagulation factor III (thromboplastin, tissue factor) | References | |
Homo sapiens | coagulation factor II (thrombin) | Starlite/ChEMBL | References |
Homo sapiens | protease, serine, 2 (trypsin 2) | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | glycoprotein Antigen 5 | coagulation factor VII (serum prothrombin conversion accelerator) | 466 aa | 384 aa | 23.7 % |
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 2 (trypsin 2) | 247 aa | 240 aa | 25.8 % |
Schistosoma mansoni | cercarial elastase (S01 family) | protease, serine, 3 | 261 aa | 234 aa | 25.2 % |
Brugia malayi | Trypsin family protein | protease, serine, 1 (trypsin 1) | 247 aa | 287 aa | 21.6 % |
Brugia malayi | Trypsin family protein | kallikrein 1 | 262 aa | 247 aa | 22.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0369 | 1 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0369 | 1 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0369 | 1 | 1 |
Echinococcus granulosus | Mastin | 0.0096 | 0 | 0.5 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0369 | 1 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.0356 | 0.9521 | 0.5 |
Echinococcus multilocularis | glycoprotein Antigen 5 | 0.0096 | 0 | 0.5 |
Echinococcus multilocularis | enteropeptidase | 0.0096 | 0 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0356 | 0.9521 | 0.5 |
Echinococcus granulosus | enteropeptidase | 0.0096 | 0 | 0.5 |
Echinococcus granulosus | glycoprotein Antigen 5 | 0.0096 | 0 | 0.5 |
Echinococcus multilocularis | Mastin | 0.0096 | 0 | 0.5 |
Onchocerca volvulus | 0.0319 | 0.8163 | 0.7669 | |
Loa Loa (eye worm) | hypothetical protein | 0.0369 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
2PT (functional) | = 1.4 uM | Anticoagulant activity in F7-deficient human plasma assessed as concentration required to double prothrombin time | ChEMBL. | 26151189 |
Ki (binding) | = 5.2 nM | Inhibition of human recombinant TF/F7a complex using S2288 as substrate preincubated for 15 mins followed by protein addition measured for 60 mins | ChEMBL. | 26151189 |
Ki (binding) | = 100 nM | Inhibition of human tissue kallikrein 1 measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 1800 nM | Inhibition of human APC measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 3000 nM | Inhibition of human trypsin measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 3300 nM | Inhibition of human F10a using S2222 as substrate measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 3600 nM | Inhibition of human plasma kallikrein using S2302 as substrate measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | = 4000 nM | Inhibition of human thrombin using S2238 as substrate measured for 30 mins | ChEMBL. | 26151189 |
Ki (binding) | > 35000 nM | Inhibition of human F9a measured for 30 mins | ChEMBL. | 26151189 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.